{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T16:37:49Z","timestamp":1769877469372,"version":"3.49.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,11]],"date-time":"2016-07-11T00:00:00Z","timestamp":1468195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,7,11]],"date-time":"2016-07-11T00:00:00Z","timestamp":1468195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adjuvants play a key role in boosting immunogenicity of vaccines, particularly for subunit protein vaccines. In this study we investigated the induction of antibody response against trivalent influenza subunit protein antigen and a saponin adjuvant, QS-21. Clinical trials of QS-21 have demonstrated the safety but, also a need of high dose for optimal immunity, which could possibly reduce patient acceptability. Here, we proposed the use of a skin delivery technology \u2013 the Nanopatch \u2013 to reduce both adjuvant and antigen dose but also retain its immune stimulating effects when compared to the conventional needle and syringe intramuscular (IM) delivery. We have demonstrated that Nanopatch delivery to skin requires only 1\/100<jats:sup>th<\/jats:sup> of the IM antigen dose to induce equivalent humoral response. QS-21 enhanced humoral response in both skin and muscle route. Additionally, Nanopatch has demonstrated 30-fold adjuvant QS-21 dose sparing while retaining immune stimulating effects compared to IM. QS-21 induced localised, controlled cell death in the skin, suggesting that the danger signals released from dead cells contributed to the enhanced immunogenicity. Taken together, these findings demonstrated the suitability of reduced dose of QS-21 and the antigen using the Nanopatch to enhance humoral responses, and the potential to increase patient acceptability of QS-21 adjuvant.<\/jats:p>","DOI":"10.1038\/srep29368","type":"journal-article","created":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T13:58:01Z","timestamp":1468331881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Potent response of QS-21 as a vaccine adjuvant in the skin when delivered with the Nanopatch, resulted in adjuvant dose sparing"],"prefix":"10.1038","volume":"6","author":[{"given":"Hwee-Ing","family":"Ng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Germain J. P.","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra C. I.","family":"Depelsenaire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A. F.","family":"Kendall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,11]]},"reference":[{"key":"BFsrep29368_CR1","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/nm.3409","volume":"19","author":"SG Reed","year":"2013","unstructured":"Reed, S. G. et al. Key roles of adjuvants in modern vaccines. Nat Med 19, 1597\u20131608, 10.1038\/nm.3409 (2013).","journal-title":"Nat Med"},{"key":"BFsrep29368_CR2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrmicro1681","volume":"5","author":"B Guy","year":"2007","unstructured":"Guy, B. The perfect mix: recent progress in adjuvant research. Nat Rev Micro 5, 505\u2013517 (2007).","journal-title":"Nat Rev Micro"},{"key":"BFsrep29368_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2471\/BLT.07.045096","volume":"86","author":"LJ Wolfson","year":"2008","unstructured":"Wolfson, L. J. et al. Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006\u20132015. Bull World Health Organ 86, 27\u201339 (2008).","journal-title":"Bull World Health Organ"},{"key":"BFsrep29368_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1046\/j.1365-3083.1998.00327.x","volume":"47","author":"Fernando","year":"1998","unstructured":"Fernando et al. Vaccine-Induced Th1-Type Responses are Dominant over Th2-Type Responses in the Short Term whereas Pre-existing Th2 Responses are Dominant in the Longer Term. Scand J Immunol 47, 459\u2013465, 10.1046\/j.1365-3083.1998.00327.x (1998).","journal-title":"Scand J Immunol"},{"key":"BFsrep29368_CR5","first-page":"2810","volume":"60","author":"T Doan","year":"2000","unstructured":"Doan, T. et al. Peripheral Tolerance to Human Papillomavirus E7 Oncoprotein Occurs by Cross-Tolerization, is Largely Th-2-independent, and is Broken by Dendritic Cell Immunization. Cancer Res 60, 2810\u20132815 (2000).","journal-title":"Cancer Res"},{"key":"BFsrep29368_CR6","doi-asserted-by":"publisher","first-page":"e10266","DOI":"10.1371\/journal.pone.0010266","volume":"5","author":"GJP Fernando","year":"2010","unstructured":"Fernando, G. J. P. et al. Potent Immunity to Low Doses of Influenza Vaccine by Probabilistic Guided Micro-Targeted Skin Delivery in a Mouse Model. PLoS ONE 5, e10266, 10.1371\/journal.pone.0010266 (2010).","journal-title":"PLoS ONE"},{"key":"BFsrep29368_CR7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jconrel.2012.07.024","volume":"162","author":"H-I Ng","year":"2012","unstructured":"Ng, H.-I. et al. Induction of potent CD8+T cell responses through the delivery of subunit protein vaccines to skin antigen-presenting cells using densely packed microprojection arrays. J Control Release 162, 477\u2013484, 10.1016\/j.jconrel.2012.07.024 (2012).","journal-title":"J Control Release"},{"key":"BFsrep29368_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S0264-410X(02)00444-9","volume":"21","author":"WR Santos","year":"2002","unstructured":"Santos, W. R. et al. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine 21, 30\u201343, 10.1016\/S0264-410X(02)00444-9 (2002).","journal-title":"Vaccine"},{"key":"BFsrep29368_CR9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4049\/jimmunol.146.2.431","volume":"146","author":"CR Kensil","year":"1991","unstructured":"Kensil, C. R. et al. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol 146, 431\u2013437 (1991).","journal-title":"J Immunol"},{"key":"BFsrep29368_CR10","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1016\/S0264-410X(01)00142-6","volume":"19","author":"DC Waite","year":"2001","unstructured":"Waite, D. C. et al. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 19, 3957\u20133967, 10.1016\/S0264-410X(01)00142-6 (2001).","journal-title":"Vaccine"},{"key":"BFsrep29368_CR11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/196953a0","volume":"196","author":"AM Glauert","year":"1962","unstructured":"Glauert, A. M. et al. Action of Saponin on Biological Cell Membranes. Nature 196, 953\u2013955 (1962).","journal-title":"Nature"},{"key":"BFsrep29368_CR12","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1074\/jbc.M115.683011","volume":"291","author":"R Marty-Roix","year":"2016","unstructured":"Marty-Roix, R. et al. Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants. J Biol Chem 291, 1123\u20131136, 10.1074\/jbc.M115.683011 (2016).","journal-title":"J Biol Chem"},{"key":"BFsrep29368_CR13","doi-asserted-by":"crossref","unstructured":"The RTS, S. C. T. P. First Results of Phase 3 Trial of RTS,S\/AS01 Malaria Vaccine in African Children. N Engl J Med 365, 1863\u20131875 10.1056\/NEJMoa1102287 (2011).","DOI":"10.1056\/NEJMoa1102287"},{"key":"BFsrep29368_CR14","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal, H. et al. Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. N Engl J Med 372, 2087\u20132096, 10.1056\/NEJMoa1501184 (2015).","journal-title":"N Engl J Med"},{"key":"BFsrep29368_CR15","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1586\/erv.11.29","volume":"10","author":"N Gar\u00e7on","year":"2011","unstructured":"Gar\u00e7on, N. & Van Mechelen, M. Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems. Expert Rev Vaccines 10, 471\u2013486, 10.1586\/erv.11.29 (2011).","journal-title":"Expert Rev Vaccines"},{"key":"BFsrep29368_CR16","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.vaccine.2014.10.078","volume":"33","author":"G Leroux-Roels","year":"2015","unstructured":"Leroux-Roels, G. et al. Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination. Vaccine 33, 1084\u20131091, 10.1016\/j.vaccine.2014.10.078 (2015).","journal-title":"Vaccine"},{"key":"BFsrep29368_CR17","unstructured":"GlaxoSmithKline P. L. C. GSK announces EU regulatory submission for malaria vaccine candidate RTS,S. Available at: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/2014\/gsk-announces-eu-regulatory-submission-for-malaria-vaccine-candidate-rtss\/. (Accessed: 30 March 2016) (2014)."},{"key":"BFsrep29368_CR18","unstructured":"GlaxoSmithKline P. L. C. Malaria vaccine candidate has demonstrated efficacy over 3\u20134 years of follow-up. Available at: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/2015\/malaria-vaccine-candidate-has-demonstrated-efficacy-over-3-4-years-of-follow-up\/. (Accessed: 30 March 2016) (2015)."},{"key":"BFsrep29368_CR19","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1016\/j.biomaterials.2010.02.022","volume":"31","author":"ML Crichton","year":"2010","unstructured":"Crichton, M. L. et al. The effect of strain rate on the precision of penetration of short densely-packed microprojection array patches coated with vaccine. Biomaterials 31, 4562\u20134572, 10.1016\/j.biomaterials.2010.02.022 (2010).","journal-title":"Biomaterials"},{"key":"BFsrep29368_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jconrel.2012.12.010","volume":"166","author":"AP Raphael","year":"2013","unstructured":"Raphael, A. P. et al. Depth-resolved characterization of diffusion properties within and across minimally-perturbed skin layers. J Control Release 166, 87\u201394, 10.1016\/j.jconrel.2012.12.010 (2013).","journal-title":"J Control Release"},{"key":"BFsrep29368_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jconrel.2011.02.026","volume":"152","author":"X Chen","year":"2011","unstructured":"Chen, X. et al. Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. J Control Release 152, 349\u2013355, 10.1016\/j.jconrel.2011.02.026 (2011).","journal-title":"J Control Release"},{"key":"BFsrep29368_CR22","doi-asserted-by":"publisher","first-page":"e67888","DOI":"10.1371\/journal.pone.0067888","volume":"8","author":"FE Pearson","year":"2013","unstructured":"Pearson, F. E. et al. Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice. PLoS ONE 8, e67888, 10.1371\/journal.pone.0067888 (2013).","journal-title":"PLoS ONE"},{"key":"BFsrep29368_CR23","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa043540","volume":"351","author":"RT Kenney","year":"2004","unstructured":"Kenney, R. T. et al. Dose Sparing with Intradermal Injection of Influenza Vaccine. N Engl J Med 351, 2295\u20132301, 10.1056\/NEJMoa043540 (2004).","journal-title":"N Engl J Med"},{"key":"BFsrep29368_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jconrel.2012.01.030","volume":"159","author":"GJP Fernando","year":"2012","unstructured":"Fernando, G. J. P. et al. Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses. J Control Release 159, 215\u2013221, 10.1016\/j.jconrel.2012.01.030 (2012).","journal-title":"J Control Release"},{"key":"BFsrep29368_CR25","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1073\/pnas.1500408112","volume":"112","author":"J Wang","year":"2015","unstructured":"Wang, J. et al. Effective and lesion-free cutaneous influenza vaccination. Proc Natl Acad Sci 112, 5005\u20135010, 10.1073\/pnas.1500408112 (2015).","journal-title":"Proc Natl Acad Sci"},{"key":"BFsrep29368_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1742-4933-11-10","volume":"11","author":"B Camilloni","year":"2014","unstructured":"Camilloni, B. et al. Antibody responses to intradermal or intramuscular MF59-adjuvanted influenza vaccines as evaluated in elderly institutionalized volunteers during a season of partial mismatching between vaccine and circulating A(H3N2) strains. Immunity & Ageing 11, 10 (2014).","journal-title":"Immunity & Ageing"},{"key":"BFsrep29368_CR27","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1038\/jid.2014.174","volume":"134","author":"ACI Depelsenaire","year":"2014","unstructured":"Depelsenaire, A. C. I. et al. Co-Localization of Cell Death with Antigen Deposition in Skin Enhances Vaccine Immunogenicity. J Invest Dermatol 134, 2361\u20132370, 10.1038\/jid.2014.174 (2014).","journal-title":"J Invest Dermatol"},{"key":"BFsrep29368_CR28","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1016\/S0264-410X(00)00415-1","volume":"19","author":"TG Evans","year":"2001","unstructured":"Evans, T. G. et al. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans. Vaccine 19, 2080\u20132091, 10.1016\/S0264-410X(00)00415-1 (2001).","journal-title":"Vaccine"},{"key":"BFsrep29368_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10544-008-9208-1","volume":"11","author":"MI Haq","year":"2009","unstructured":"Haq, M. I. et al. Clinical administration of microneedles: skin puncture, pain and sensation. Biomed Microdevices 11, 35\u201347, 10.1007\/s10544-008-9208-1 (2009).","journal-title":"Biomed Microdevices"},{"key":"BFsrep29368_CR30","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1097\/AJP.0b013e31816778f9","volume":"24","author":"HS Gill","year":"2008","unstructured":"Gill, H. S. et al. Effect of microneedle design on pain in human volunteers. The Clinical journal of pain 24, 585\u2013594, 10.1097\/AJP.0b013e31816778f9 (2008).","journal-title":"The Clinical journal of pain"},{"key":"BFsrep29368_CR31","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/mus.20062","volume":"29","author":"WR Kennedy","year":"2004","unstructured":"Kennedy, W. R. Opportunities afforded by the study of unmyelinated nerves in skin and other organs. Muscle Nerve 29, 756\u2013767, 10.1002\/mus.20062 (2004).","journal-title":"Muscle Nerve"},{"key":"BFsrep29368_CR32","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nchem.1963","volume":"6","author":"A Fern\u00e1ndez-Tejada","year":"2014","unstructured":"Fern\u00e1ndez-Tejada, A. et al. Development of a minimal saponin vaccine adjuvant based on QS-21. Nat Chem 6, 635\u2013643, 10.1038\/nchem.1963 (2014).","journal-title":"Nat Chem"},{"key":"BFsrep29368_CR33","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1006\/viro.1998.9060","volume":"243","author":"MM McNeal","year":"1998","unstructured":"McNeal, M. M. et al. Stimulation of Local Immunity and Protection in Mice by Intramuscular Immunization with Triple- or Double-Layered Rotavirus Particles and QS-21. Virology 243, 158\u2013166, 10.1006\/viro.1998.9060 (1998).","journal-title":"Virology"},{"key":"BFsrep29368_CR34","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.vaccine.2010.10.084","volume":"29","author":"D Safari","year":"2011","unstructured":"Safari, D. et al. Codelivery of adjuvants at the primary immunization site is essential for evoking a robust immune response to neoglycoconjugates. Vaccine 29, 849\u2013854, 10.1016\/j.vaccine.2010.10.084 (2011).","journal-title":"Vaccine"},{"key":"BFsrep29368_CR35","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1586\/erv.11.18","volume":"10","author":"G Ragupathi","year":"2011","unstructured":"Ragupathi, G. et al. Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer. Expert Rev Vaccines 10, 463\u2013470, 10.1586\/erv.11.18 (2011).","journal-title":"Expert Rev Vaccines"},{"key":"BFsrep29368_CR36","unstructured":"US Food and Drug Administration. Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines. Available at: http:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Vaccines\/ucm074786.htm. (Accessed: 30 March 2016) (2014)."},{"key":"BFsrep29368_CR37","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1016\/S0264-410X(02)00209-8","volume":"20","author":"G Liu","year":"2002","unstructured":"Liu, G. et al. QS-21 structure\/function studies: effect of acylation on adjuvant activity. Vaccine 20, 2808\u20132815, 10.1016\/S0264-410X(02)00209-8 (2002).","journal-title":"Vaccine"},{"key":"BFsrep29368_CR38","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1016\/S0264-410X(03)00175-0","volume":"21","author":"D Chen","year":"2003","unstructured":"Chen, D. et al. Epidermal powder immunization of mice and monkeys with an influenza vaccine. Vaccine 21, 2830\u20132836, 10.1016\/S0264-410X(03)00175-0 (2003).","journal-title":"Vaccine"},{"key":"BFsrep29368_CR39","doi-asserted-by":"publisher","first-page":"15ra15","DOI":"10.1126\/scitranslmed.3000624","volume":"2","author":"S Khurana","year":"2010","unstructured":"Khurana, S. et al. Vaccines with MF59 Adjuvant Expand the Antibody Repertoire to Target Protective Sites of Pandemic Avian H5N1 Influenza Virus. Sci Transl Med 2, 15ra15, 10.1126\/scitranslmed.3000624 (2010).","journal-title":"Sci Transl Med"},{"key":"BFsrep29368_CR40","unstructured":"Siegrist, C.-A. In Vaccines (eds Plotkin, S., Orenstein, W. & Offit, P. ) Ch. 2, 17\u201336 (Saunders Elsevier, 2008)."},{"key":"BFsrep29368_CR41","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.virol.2007.07.017","volume":"369","author":"L Lai","year":"2007","unstructured":"Lai, L. et al. GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6 P challenge by a DNA\/MVA immunodeficiency virus vaccine. Virology 369, 153\u2013167 (2007).","journal-title":"Virology"},{"key":"BFsrep29368_CR42","doi-asserted-by":"publisher","first-page":"85ra48","DOI":"10.1126\/scitranslmed.3002336","volume":"3","author":"S Khurana","year":"2011","unstructured":"Khurana, S. et al. MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines. Sci Transl Med 3, 85ra48, 10.1126\/scitranslmed.3002336 (2011).","journal-title":"Sci Transl Med"},{"key":"BFsrep29368_CR43","doi-asserted-by":"crossref","unstructured":"Tufail, S. et al. Tissue specific heterogeneity in effector immune cell response. Front Immunol 4, 10.3389\/fimmu.2013.00254 (2013).","DOI":"10.3389\/fimmu.2013.00254"},{"key":"BFsrep29368_CR44","doi-asserted-by":"publisher","first-page":"e35083","DOI":"10.1371\/journal.pone.0035083","volume":"7","author":"RPJ Lai","year":"2012","unstructured":"Lai, R. P. J. et al. Mixed Adjuvant Formulations Reveal a New Combination That Elicit Antibody Response Comparable to Freund\u2019s Adjuvants. PLoS ONE 7, e35083, 10.1371\/journal.pone.0035083 (2012).","journal-title":"PLoS ONE"},{"key":"BFsrep29368_CR45","doi-asserted-by":"crossref","unstructured":"Yam, K. K. et al. Unusual patterns of IgG avidity in some young children following two doses of the adjuvanted pandemic H1N1 (2009) influenza virus vaccine. Clin Vaccine Immunol 20, 459-467, 10.1128\/cvi.00619-12 (2013).","DOI":"10.1128\/CVI.00619-12"},{"key":"BFsrep29368_CR46","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","volume":"33","author":"RL Coffman","year":"2010","unstructured":"Coffman, R. L. et al. Vaccine Adjuvants: Putting Innate Immunity to Work. Immunity 33, 492\u2013503, http:\/\/dx.doi.org\/10.1016\/j.immuni.2010.10.002 (2010).","journal-title":"Immunity"},{"key":"BFsrep29368_CR47","doi-asserted-by":"publisher","first-page":"45135","DOI":"10.1074\/jbc.M307417200","volume":"278","author":"W Zhong","year":"2003","unstructured":"Zhong, W. et al. Genome-wide Characterization of a Viral Cytotoxic T Lymphocyte Epitope Repertoire. J Biol Chem 278, 45135\u201345144, 10.1074\/jbc.M307417200 (2003).","journal-title":"J Biol Chem"},{"key":"BFsrep29368_CR48","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4049\/jimmunol.182.1.29","volume":"182","author":"E Ingulli","year":"2009","unstructured":"Ingulli, E. et al. Cutting Edge: Antigen Presentation to CD8 T Cells after Influenza A Virus Infection. J Immunol 182, 29\u201333, 10.4049\/jimmunol.182.1.29 (2009).","journal-title":"J Immunol"},{"key":"BFsrep29368_CR49","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jconrel.2011.10.026","volume":"158","author":"X Chen","year":"2012","unstructured":"Chen, X. et al. Rapid kinetics to peak serum antibodies is achieved following influenza vaccination by dry-coated densely packed microprojections to skin. J Control Release 158, 78\u201384, 10.1016\/j.jconrel.2011.10.026 (2012).","journal-title":"J Control Release"},{"key":"BFsrep29368_CR50","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s12026-013-8400-4","volume":"56","author":"S Cerpa-Cruz","year":"2013","unstructured":"Cerpa-Cruz, S. et al. Adverse events following immunization with vaccines containing adjuvants. Immunol Res 56, 299\u2013303, 10.1007\/s12026-013-8400-4 (2013).","journal-title":"Immunol Res"},{"key":"BFsrep29368_CR51","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","volume":"82","author":"N Petrovsky","year":"2004","unstructured":"Petrovsky, N. & Aguilar, J. C. Vaccine adjuvants: Current state and future trends. Immunol Cell Biol 82, 488\u2013496 (2004).","journal-title":"Immunol Cell Biol"},{"key":"BFsrep29368_CR52","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/0264-410X(95)00011-O","volume":"13","author":"RK Gupta","year":"1995","unstructured":"Gupta, R. K. & Siber, G. R. Adjuvants for human vaccines\u2014current status, problems and future prospects. Vaccine 13, 1263\u20131276, 10.1016\/0264-410X(95)00011-O (1995).","journal-title":"Vaccine"},{"key":"BFsrep29368_CR53","doi-asserted-by":"crossref","unstructured":"Wang, L. et al. Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6\u201335 Months of Age During 2013\u20132014: Results From A Phase II Randomized Trial. J Pediatric Infect Dis Soc 10.1093\/jpids\/piv041 (2015).","DOI":"10.1093\/jpids\/piv041"},{"key":"BFsrep29368_CR54","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.coi.2013.12.004","volume":"26","author":"H Kono","year":"2014","unstructured":"Kono, H. et al. Molecular determinants of sterile inflammation. Curr Opin Immunol 26, 147\u2013156, 10.1016\/j.coi.2013.12.004 (2014).","journal-title":"Curr Opin Immunol"},{"key":"BFsrep29368_CR55","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nm1603","volume":"13","author":"C-J Chen","year":"2007","unstructured":"Chen, C.-J. et al. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 13, 851\u2013856 (2007).","journal-title":"Nat Med"},{"key":"BFsrep29368_CR56","doi-asserted-by":"publisher","first-page":"21095","DOI":"10.1073\/pnas.1319784110","volume":"110","author":"M Vono","year":"2013","unstructured":"Vono, M. et al. The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination. Proc Natl Acad Sci USA 110, 21095\u201321100, 10.1073\/pnas.1319784110 (2013).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep29368_CR57","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.vaccine.2010.12.090","volume":"29","author":"S Calabro","year":"2011","unstructured":"Calabro, S. et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29, 1812\u20131823, 10.1016\/j.vaccine.2010.12.090 (2011).","journal-title":"Vaccine"},{"key":"BFsrep29368_CR58","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1039\/C2RA20153D","volume":"2","author":"D Jenkins","year":"2012","unstructured":"Jenkins, D. et al. High density and high aspect ratio solid micro-nanoprojection arrays for targeted skin vaccine delivery and specific antibody extraction. RSC Adv 2, 3490\u20133495, 10.1039\/C2RA20153D (2012).","journal-title":"RSC Adv"},{"key":"BFsrep29368_CR59","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jconrel.2009.06.029","volume":"139","author":"X Chen","year":"2009","unstructured":"Chen, X. et al. Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin. J Control Release 139, 212\u2013220, 10.1016\/j.jconrel.2009.06.029 (2009).","journal-title":"J Control Release"},{"key":"BFsrep29368_CR60","unstructured":"Victorian Infectious Diseases Reference Laboratory. Reagents for the Typing of Human Influenza Isolates 2013. Available at: (Accessed: 13 October 2014) (2013)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep29368.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep29368","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep29368.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T06:53:21Z","timestamp":1672901601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep29368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,11]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,7,29]]}},"alternative-id":["BFsrep29368"],"URL":"https:\/\/doi.org\/10.1038\/srep29368","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,11]]},"assertion":[{"value":"31 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A.F.K. has a financial interest in the commercialisation of the Nanopatch technology. This includes him performing roles in Vaxxas Pty Ltd (e.g. Founder, Chief Technology Officer and a Director). All the authors are inventors on patents licenced to Vaxxas. G.J.P.F. was partially employed by Vaxxas Pty Ltd. as a Senior Vaccinologist and H.I.N. was casually employed by Vaxxas Pty Ltd. as a Coating and Formulation Scientist.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29368"}}